(NZ)-N-(3-methylcyclohexylidene)hydroxylamine | 4701-95-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (NZ)-N-(3-methylcyclohexylidene)hydroxylamine
• CAS: 4701-95-5
• 化学式: C₇H₁₃NO
• 分子量: 127.18
• InChiKey: XHUKUULKCNZFAG-FPLPWBNLSA-N

物化性质

• 沸点：
  115 °C(Press: 15 Torr)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof
  申请人：Hardy Larry Wendell

  公开号：US20110319380A1

  公开（公告）日：2011-12-29

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。本文中提供的化合物可用于治疗、预防和/或管理各种疾病，如神经系统疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5(mGluR5)的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Novira Therapeutics, Inc.

  公开号：US20160185779A1

  公开（公告）日：2016-06-30

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了用于治疗需要治疗HBV感染患者的化合物，其制药组合物，以及抑制、抑制或预防该患者HBV感染的方法。
• Derivatives and methods of treating hepatitis B infections
  申请人：Novira Therapeutics, Inc.

  公开号：US10077264B2

  公开（公告）日：2018-09-18

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了用于治疗有需要的受试者 HBV 感染的化合物、其药物组合物以及抑制、抑制或预防受试者 HBV 感染的方法。
• Curable photochromic composition including a segmented polymer
  申请人：Transitions Optical, Ltd.

  公开号：US11525027B2

  公开（公告）日：2022-12-13

  The present invention relates to a curable photochromic composition that includes: (a) a photochromic compound; and (b) a segmented polymer that includes active hydrogen groups, at least one first segment, and at least one second segment, in which, (i) each first segment independently includes a (meth)acrylic polymer segment, and (ii) each second segment independently includes at least one of, a polycarbonate segment, a polyester segment, a polyether segment, a polyurethane segment, and combinations of two or more thereof. The curable photochromic composition further includes (c) a curing agent having reactive functional groups that are reactive with the active hydrogen groups of the segmented polymer (a), in which the curing agent includes at least one of, a polyisocyanate, a polyisothiocyanate, and an aminoplast. The present invention also relates to photochromic articles that include at least one layer formed from the curable photochromic composition of the present invention.

  本发明涉及一种可固化的光致变色组合物，该组合物包括(a) 光致变色化合物；和 (b) 包括活性氢基、至少一个第一段和至少一个第二段的分段聚合物，其中，(i) 每个第一段独立地包括（甲基）丙烯酸聚合物段，和 (ii) 每个第二段独立地包括聚碳酸酯段、聚酯段、聚醚段、聚氨酯段中的至少一种，以及其中两种或两种以上的组合。可固化的光致变色组合物还包括(c)具有与分段聚合物(a)的活性氢基反应的活性官能团的固化剂，其中固化剂包括多异氰酸酯、多异硫氰酸盐和氨基树脂中的至少一种。本发明还涉及光致变色物品，该物品包括至少一层由本发明的可固化光致变色组合物形成的层。